Endocannabinoids and their role in fatty liver disease

Digestive Diseases

Volumn 28, Issue 1, 2010, Pages 261-266

  Mallat, A ^a,b,c   Lotersztajn, S ^b,c  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Cannabinoids; Fatty liver disease; Rimonabant

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; ADIPOCYTOKINE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; LIPOPROTEIN LIPASE; PHOSPHOLIPASE D; RIMONABANT;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ANXIETY; CANNABIS SMOKING; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; DYSLIPIDEMIA; FATTY LIVER; FIBROGENESIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; LIVER FIBROSIS; NAUSEA; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; SLEEP DISORDER;

ANIMALS; ENDOCANNABINOIDS; FATTY LIVER; HUMANS; HYPERTENSION, PORTAL; INFLAMMATION; INSULIN RESISTANCE; LIVER CIRRHOSIS; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID;

EID: 77952573550     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000282100     Document Type: Review

References (53)

1. Cortez-Pinto H, de Moura MC, Day CP: Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 2006;44:197-208.
2. Parekh S, Anania FA: Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007;132:2191-2207.
3. Ong JP, Younossi ZM: Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007;11:1-16, vii.
4. Ratziu V, Poynard T: Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology 2006;44:802-805.
5. Mallat A, Lotersztajn S: Endocannabinoids as novel mediators of liver diseases. J Endocrinol Invest 20 06;29: 58-65.
6. Pacher P, Batkai S, Kunos G: The endocan-nabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389-462.
7. Di Marzo V: Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008;7:438-455.
8. Mallat A, Lotersztajn S: Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Am J Physiol Gastrointest Liver Physiol 2008;294:G9-G12.
9. Klein TW: Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005;5:400-411.
10. Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, Manin S, Tran-Van-N hieu J, Karsak M, Zimmer A, Mallat A: CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol 2008;153:286-289.
11. Guzman M, Galve-Roperh I, Sanchez C: Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol Sci 2001;22:19-22.
12. Kunos G, Osei-Hyiaman D, Liu J, Godlewski G, Batkai S: Endocannabinoids and the control of energy homeostasis. J Biol Chem 2008;283:33021-33025.
13. Pertwee RG: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, canna-bidiol and delta9- tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215.
14. Piomelli D, Giuffrida A, Calignano A, Rodriguez de Fonseca F: The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000;21:218-224.
15. Di Marzo V, Bifulco M, De Petrocellis L: The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004;3:771-784.
16. Ros J, Claria J, To-Figueras J, Planaguma A, Cejudo-Martin P, Fernandez-Varo G, Martin-Ruiz R, Arroyo V, Rivera F, Rodes J, Jimenez W: Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002;122:85-93.
17. Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J, Wang L, Mirshahi F, Khanolkar AD, Makriyannis A, Urbaschek R, Garcia N Jr, Sanyal AJ, Kunos G: Endocanna-binoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001;7:827-832.
18. Jeong WI, Osei-Hyiaman D, Park O, Liu J, Batkai S, Mukhopadhyay P, Horiguchi N, Harvey-White J, Marsicano G, Lutz B, Gao B, Kunos G: Paracrine activation of hepatic CB1 receptors by stellate cell-derived endo-cannabinoids mediates alcoholic fatty liver. Cell Metab 2008;7:227-235.
19. Osei-Hyiaman D, Depetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G: Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115:1298-1305.
20. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, Batkai S, Marsicano G, Lutz B, Buettner C, Kunos G: Hepatic CB1 receptor is required for development of diet-induced ste atosis, dysl ipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008;118:3160-3169.
21. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, Serriere-Lanneau V, Ledent C, Mallat A, Lotersztajn S: CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006;12:671-676.
22. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, Zimmer A, Mallat A, Lotersztajn S: Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005;128:74 2-755.
23. Janero DR, Makriyannis A: Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs 2009;14:43-65.
24. Despres JP, Golay A, Sjostrom L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134.
25. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-775.
26. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S: Effects of the canna-binoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:1-year experience from the RIO-Europe study. Lancet 2005;365:1389-1397. (Pubitemid 40523733)
27. Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O: Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J 2008;29:1761-1771.
28. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, Penarier G, Soubrie P, Le Fur G, Galiegue S, Casellas P: The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy ba lance. FASEB J 2005;19:1567-1569.
29. Liu YL, Connoley IP, Wilson CA, Stock MJ: Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005;29:183-187.
30. Esposito I, Proto MC, Gazzerro P, Laezza C, Miele C, Alberobello AT, D'Esposito V, Beguinot F, Formisano P, Bifulco M: The can-nabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 2008;74:1678-1686.
31. Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschop J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, Fekete C, Reizes O, Rohner-Jeanrenaud F, Tschop MH: Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 2008;57: 2977-29 91.
32. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, Chabbert M, Cruccioli N, Pfersdorff C, Roque C, Arnone M, Croci T, Soubrie P, Oury-Donat F, Maffrand JP, Scatton B, Lacheretz F, Le Fur G, Herbert JM, Bensaid M: Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007;46:122-129.
33. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63:908-914.
34. Scheen AJ, Finer N, Hollander P, Jensen MD, Va n Gaal LF: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-1672.
35. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, Despres JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM: Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARI-US randomized controlled trial. JAMA 2008;299:1547-1560.
36. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A: SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 2008;31:2169-2176.
37. Després JP, Ross R, Boka G, Alméras N, Lemieux I, ADAGIO-Lipids Investigators: Effect of rimonabant on the high-triglyceride/low- HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009;29:416-423.
38. Lunn CA, Reich EP, Fine JS, Lavey B, Kozlowski JA, Hipkin RW, Lundell DJ, Bober L: Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br J Pharmacol 2008;153:226-239.
39. Lin J, Yang R, Tarr PT, Wu PH, Handschin C, Li S, Yang W, Pei L, Uldry M, Tontonoz P, Newgard CB, Spiegelman BM: Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SR EBP. Cell 2005;120:261-273.
40. Postic C, Girard J: Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008;118:829-838.
41. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P: Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003;284:R345-R353.
42. Flamment M, Gueg uen N, Wetter wald C, Simard G, Malthiery Y, Ducluzeau PH: Effects of the cannabinoid CB1 antagonist, rimonabant, on hepatic mitochondrial function in rats fed a high fat diet. Am J Physiol Endocrinol Metab 2009, E-pub ahead of print.
43. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
44. Hezode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, Medkour F, Pawlostky JM, Lotersztajn S, Mallat A: Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008;134:432-439.
45. Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006;444:860-867.
46. Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S, Nhieu JT, Belot MP, Zimmer A, Even P, Cani PD, Knauf C, Burcel in R, Bertola A, Le Marchand-Brustel Y, Gual P, Mallat A, Lotersztajn S: Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One 2009;4:e5844.
47. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM, Jordan J: Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838-2843.
48. Gonthier MP, Hoareau L, Festy F, Matias I, Valenti M, Bes-Houtmann S, Rouch C, Robert-Da Silva C, Chesne S, Lefebvre d'Hellencourt C, Cesari M, Di Marzo V, Roche R: Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring) 2007;15:837-845.
49. Munoz-Luque J, Ros J, Fernandez-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, Friedman SL, Arroyo V, Jimenez W: Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008;324:475-483.
50. DeLeve LD, Wang X, Kanel GC, Atkinson RD, McCuskey RS: Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. Am J Pathol 2008;173:993-1001.
51. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, Pawlotsky JM, Dhumeaux D, Lotersztajn S, Mallat A: Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C. Hepatology 2005;42:63-71.
52. Ishida JH, Peters MG, Jin C, Louie K, Tan V, Bacchetti P, Terrault NA: Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 2008;6:69-75.
53. Tam Y, Liu J, Bátkai S, Osei-Hyiaman D, Makryiannis AV, Vemuri K, Sharkey KA, Kunos G: Anti-obesity effects of a novel peripherally acting neutral cannabinoid 1 receptor antagonist in mice. 19th annual symposium on the cannabinoids. Burlington, Vermont, International Cannabinoid Research Society, p 54.